INSPIRE: bladder-sparing chemoRT with durvalumab in LN+ urothelial cancer скачать в хорошем качестве

INSPIRE: bladder-sparing chemoRT with durvalumab in LN+ urothelial cancer

Monika Joshi, MD, MRCP, Penn State Cancer Institute, Hershey, PA, gives an outline of the ongoing Phase II INSPIRE study (NCT04216290), also known as EA8185, investigating bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, lymph node-positive (LN+) urothelial cancer. The aim of the INSPIRE study is to determine the role of concurrent and adjuvant durvalumab in an LN+ bladder cancer population who have previously been treated with induction chemotherapy followed by concurrent chemoRT. The study will enrol 114 patients and the primary endpoint of the trial is clinical complete response. This interview took place during the 2021 Genitourinary Cancers Symposium.